| Literature DB >> 35517746 |
Imran Khan1,2, Haibo Zhang1,3, Wei Liu1,4, Liping Zhang1,3, Fang Peng5, Yuchan Chen6, Qingbo Zhang1,3, Guangtao Zhang1,3, Weimin Zhang6, Changsheng Zhang1,3.
Abstract
Extracts from Antarctic-derived Penicillium chrysogenum CCTCC M 2020019 showed potent antibacterial bioactivities. We report herein the isolation of chrysonin (1), a new compound containing a pair of enantiomers 6S- and 6R-chrysonin (1a and 1b) featuring an unprecedented eight-membered heterocycle fused with a benzene ring. Compound 2, a mixture consisting of a new zwitterionic compound chrysomamide (2a) and N-[2-trans-(4-hydroxyphenyl) ethenyl] formamide (2b) in a ratio around 1 : 2.8, was isolated together with seven known compounds 3-9. Chemical structures of all compounds were determined by comprehensive spectroscopic analyses. The isolated compounds were evaluated for antimicrobial, cytotoxic and alpha-glucosidase inhibition activities. Chrysonin (1) showed moderate alpha-glucosidase inhibitory activity. The dominant product xanthocillin X (4) displayed potent inhibition activities against Gram-negative pathogens Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa with MIC values at 0.125 μg mL-1. Xanthocillins X (4) and Y1 (5) also showed significant cytotoxicities against four cancer cell lines with IC50 values ranging from 0.26 to 5.04 μM. This study highlights that microorganisms from polar regions are emerging as a new resource for the discovery of natural products combating human pathogens. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35517746 PMCID: PMC9054296 DOI: 10.1039/d0ra03529g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structures of 1–9.
1H and 13C-NMR data of compounds 1, 2a, 2b and 3
| No. | 1 | 2a | 2b | 3 | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 1 | 123.5, CH | 7.16 (dd, 10.5, 14.7), overlap | 118.9, CH | 7.21 (dd, 10.5, 14.7) | 117.8, CH | 6.64 (t, 9.8) | ||
| 2 | 151.1, C | 110.6, CH | 5.93 (d, 14.7) | 113.2, CH | 6.14 (d, 14.7) | 110.9, CH | 5.60 (d, 9.8) | |
| 3 | 130.4, C | 127.2, C | 126.9, C | 126.1, C | ||||
| 4 | 126.2, CH | 7.12 (d, 8.4) | 126.6, CH | 7.16 (d, 8.4) | 129.6, CH | 7.19 (d, 8.4) | ||
| 5 | 180.2, C | 115.5, CH | 6.67 (d, 8.4) | 115.6, CH | 6.69 (d, 8.4) | 115.5, CH | 6.75 (d, 8.4) | |
| 6 | 62.6, C | 155.9, C | 156.3, C | 156.3, C | ||||
| 7 | 44.5, CH2 | 2.07 (d, 14.0), 2.25 (d, 14.0) | 115.5, CH | 6.67 (d, 8.4) | 115.6, CH | 6.69 (d, 8.4) | 115.5, CH | 6.75 (d, 8.4) |
| 8 | 81.6, C | 126.2, CH | 7.12 (d, 8.4) | 126.6, CH | 7.16 (d, 8.4) | 129.6, CH | 7.19 (d, 8.4) | |
| 9 | 115.0, CH | 6.85 (d, 7.7) | 163.6, CH | 8.36 (d, 10.5) | 158.6, CH | 8.06 s | 160.1, CH | 8.10 s |
| 10 | 125.3, CH | 6.95 (t, 7.7) | ||||||
| 11 | 120.9, CH | 6.78 (d, 7.7) | ||||||
| 12 | 123.2, CH | 6.94 (t, 7.7) | ||||||
| 13 | 29.7, CH3 | 1.13, s | ||||||
| 14 | 29.9, CH3 | 1.43, s | ||||||
| 15 | 27.7, CH3 | 1.62, s | ||||||
| NH | 6.49, brs | 10.04 (t, 10.5) | 10.15 (d, 10.5) | 9.80 (d, 10.5) | ||||
| OH | 3.70, brs | 9.40, brs | 9.40, brs | 9.52, brs | ||||
Recorded in CDCl3, 1H at 700 MHz, 13C at 175 MHz.
Recorded in DMSO-d6, 1H at 700 MHz, 13C at 175 MHz.
Fig. 2Selected key COSY, HMBC and NOESY correlations of 1 (A) and comparison of experimental ECD spectra of 1a and 1b with those calculated for 6R or 6S configurations (B).
Fig. 3(A) Single crystal X-ray structures of compounds 2b and 4 (in DMSO). The ellipsoids of non-hydrogen atoms are shown at 50% probability levels. (B) Comparison of different types of proton signals of compounds 2a, 2b and 3. (C) Two alternative routes A and B to generate putative structures of 2a from 2b. (D) Selected key COSY, HMBC and NOESY correlations of 2a.
Antibacterial activities of compounds 1–9 (MIC, μg mL−1)
|
|
|
|
|
| MRSA, shhs-A1 |
| |
|---|---|---|---|---|---|---|---|
| 1 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 2 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 3 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 4 | 0.125 | 0.25 | 0.125 | 0.125 | 0.125 | 0.25 | 0.25 |
| 5 | 0.5 | 0.5 | 4 | 8 | 1 | 8 | 16 |
| 6 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 7 | 64 | 64 | >64 | >64 | 32 | 64 | >64 |
| 8 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| 9 | >64 | >64 | >64 | >64 | >64 | >64 | >64 |
| Vm | 32 | 0.25 | >64 | >64 | 0.25 | 0.25 | 0.5 |
| Sm | 2 | 2 |
Vancomycin.
Streptomycin.
Cytotoxic activities of compounds 4, 5 and 7 (IC50a, μM)
| SF-268 | MCF-7 | HepG-2 | A549 | |
|---|---|---|---|---|
| 2 | 32.75 ± 3.25 | 58.07 ± 5.54 | 50.44 ± 2.07 | 42.87 ± 1.95 |
| 4 | 1.23 ± 0.13 | 0.26 ± 0.03 | 1.34 ± 0.05 | 0.38 ± 0.03 |
| 5 | 2.11 ± 0.01 | 3.65 ± 0.07 | 4.50 ± 0.03 | 5.04 ± 0.22 |
| 6 | 25.31 ± 0.86 | 76.74 ± 2.34 | 46.81 ± 2.07 | 52.61 ± 1.30 |
| 7 | 7.12 ± 0.57 | 35.23 ± 3.94 | 6.79 ± 0.57 | 25.60 ± 2.38 |
| Amycin | 1.06 ± 0.06 | 1.47 ± 0.14 | 1.21 ± 0.01 | 1.36 ± 0.01 |
Values are expressed as the means ± SD from three independent experiments.